Calgary, Alberta – TheNewswire - January 17, 2022 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV:OTC) is pleased to announce a partnership with Bioana SAPI de CV (“Bioana”), a female-led medical device development company based in Monterey, Mexico.

Bioana was founded by three female biomedical engineering students after graduation in 2013.

Bioana has extensive experience in feasibility studies, concept development, design for manufacturing, small batch prototype production, verification and validation testing, FDA clearance and approval, and development of intellectual property and branding.

“Bioana has been exceptional to work with as we prepare for preclinical studies,” said Dr. Mark Lee, President & CEO of Ocumetics. “Over the past several months, Bioana designed, fabricated and produced high quality Bionic Lens™ prototypes for Ocumetics and consistently delivered the prototypes ahead of schedule. We applaud and encourage their commitment to innovation and excellence,” adds Dr. Lee.

“Their ‘can-do’ attitude is what really distinguishes Bioana,” says Dr. Garth Webb, Founder & Chief Scientific Officer for Ocumetics. “They genuinely enjoy engineering challenges and thrive while working on creative and innovation projects, such as the Bionic Lens™. Whatever we throw at them design-wise, they have risen to the occasion. We look forward to a long and successful partnership with Bioana on the Bionic Lens™ and future products,” adds Dr. Webb.

“Working on the Bionic Lens™ project has been a great experience,” said Adriana Torres, Founder & CCO of Bioana. “We have enjoyed working with the incredible team at Ocumetics. Their passion for driving their mission to fruition is a great inspiration for our team. Our common values and enthusiasm for innovation ensure a successful collaboration, where we have become an extension of their team making the success of the Bionic Lens™ our priority too,” adds Ms. Torres.

About Ocumetics

Ocumetics Technology Corp. (TSXV:“OTC”) is a Canadian research and product development company that specializes in adaptive lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry - the Bionic Lens™.  The Bionic Lens™ is an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.  

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.